Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 45: 1797-1802, 1999;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (18)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Martínez, J. M.
Right arrow Articles by Ramírez, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martínez, J. M.
Right arrow Articles by Ramírez, M.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 1999;45:1797-1802.)
© 1999 American Association for Clinical Chemistry, Inc.

Articles

Aminopeptidase Activities in Breast Cancer Tissue

José M. Martínez1, Isabel Prieto1, María J. Ramírez1, Cristobal Cueva2, Francisco Alba3 and Manuel Ramírez1,a

1 Área de Fisiología, Universidad de Jaén, Edif. B-3, 23071 Jaén, Spain.

2 Hospital General de Especialidades Ciudad de Jaén, 23005 Jaén, Spain.

3 Departamento de Bioquímica y Biología Molecular, Universidad de Granada, 18071 Granada, Spain.
a Author for correspondence. Fax 34-953-212141; e-mail msanchez{at}ujaen.es

Background: Endopeptidases such as cathepsins help determine the prognosis of breast cancer (BC). However, little information is available about the role in BC of aminopeptidases (APs), which have been implicated in the metabolism of several local hormonal factors.

Methods: Using aminoacyl-ß-naphthylamides as substrates, we measured fluorometrically alanyl-AP, arginyl-AP, cystinyl-AP, glutamyl-AP, aspartyl-AP, and pyroglutamyl-AP activities in their soluble and membrane-bound forms in surgically removed BC tissue from which we separated samples of neoplastic, adjacent tumoral, and unaffected surrounding tissue.

Results: Compared with unaffected tissue, neoplastic tissue had significantly higher activities of soluble alanyl-AP (553.9 ± 82.8 vs 1615.2 ± 183.0 pmol/mg protein; P <0.001), arginyl-AP (372.4 ± 56.6 vs 1027.2 ± 143.5 pmol/mg protein; P <0.001), and cystinyl-AP (74.8 ± 10.0 vs 282.9 ± 37.2 pmol/mg protein; P <0.001), and of membrane-bound arginyl-AP (457.7 ± 97.9 vs 886.6 ± 140.0 pmol/mg protein; P <0.01). However, membrane-bound aspartyl-AP activity was significantly lower in neoplastic tissue (17.3 ± 1.4 vs 9.2 ± 1.2 pmol/mg protein; P <0.05) and pyroglutamyl-AP activity was significantly lower in neoplastic and adjacent tissues (12.8 ± 0.9 vs 7.0 ± 1.2 and 8.0 ± 1.3 pmol/mg protein; P <0.001 for both comparisons).

Conclusions: The present results document changes in AP activities in BC tissue. These changes may reflect the functional status of the AP substrates, which can be selectively activated or inhibited locally in the affected tissue as a result of specific conditions brought about by the tumor.




The following articles in journals at HighWire Press have cited this article:


Home page
 Molecular Cancer TherapeuticsHome page
M. Wickstrom, J. I. Johnsen, F. Ponthan, L. Segerstrom, B. Sveinbjornsson, M. Lindskog, H. Lovborg, K. Viktorsson, R. Lewensohn, P. Kogner, et al.
The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo
Mol. Cancer Ther., September 1, 2007; 6(9): 2409 - 2417.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
A. Varona, L. Blanco, J. I. Lopez, J. Gil, E. Agirregoitia, J. Irazusta, and G. Larrinaga
Altered levels of acid, basic, and neutral peptidase activity and expression in human clear cell renal cell carcinoma
Am J Physiol Renal Physiol, February 1, 2007; 292(2): F780 - F788.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Gullbo, C. Wallinder, M. Tullberg, H. Lovborg, H. Ehrsson, R. Lewensohn, P. Nygren, K. Luthman, and R. Larsson
Antitumor activity of the novel melphalan containing tripeptide J3 (L-prolyl-L-melphalanyl-p-L-fluorophenylalanine ethyl ester): Comparison with its m-L-sarcolysin analogue P2
Mol. Cancer Ther., December 1, 2003; 2(12): 1331 - 1339.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American Association for Clinical Chemistry.